The company said reported net sales rose 11.8% to $5.8 billion in Q4 2023, and reported net sales for the full year rose 11.1% to $20.5 billion. It said organic net sales grew 11.4% in Q4 and 11.5% for the full year.

1. 01

   The company said reported net sales rose 11.8% to $5.8 billion in Q4 2023, and reported net sales for the full year rose 11.1% to $20.5 billion. It said organic net sales grew 11.4% in Q4 and 11.5% for the full year.

2. 02

   Stryker said reported EPS for the full year 2023 rose 33.7% to $8.25, and adjusted EPS rose 13.5% to $10.60. It said reported EPS for Q4 rose 102.7% to $2.98, and adjusted EPS rose 15.3% to $3.46.

3. 03

   The company reported net cash provided by operating activities of $3,680 million for the full year 2023. Over the same period, it used $(390) million for acquisitions, net of cash acquired, and $(1,139) million for dividend payments.

4. 04

   The company said it expects organic net sales growth of 7.5% to 9.0% for the full year 2024, and adjusted net earnings per diluted share of $11.70 to $12.00. It also said that if foreign exchange rates remain near current levels, adjusted EPS would be negatively affected by approximately $0.05 to $0.10, and that this impact is included in its guidance.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.